about
Investigating suspected pulmonary embolism in pregnancyAnatomic and functional imaging of metastatic carcinoid tumorsNeuroendocrine tumours of the head and neck: anatomical, functional and molecular imaging and contemporary management.Accuracy of [18Fluorine]-Fluoro-2-Deoxy-d-Glucose Positron Emission Tomography-Computed Tomography Response Assessment Following (Chemo)radiotherapy for Locally Advanced Laryngeal/Hypopharyngeal Carcinoma.[18F]FDG PET/CT imaging of colorectal cancer: a pictorial review.Alterations in anatomic and functional imaging parameters with repeated FDG PET-CT and MRI during radiotherapy for head and neck cancer: a pilot study.MRI appearances of müllerian duct abnormalities.Multimodality imaging with CT, MR and FDG-PET for radiotherapy target volume delineation in oropharyngeal squamous cell carcinoma.Recurrent solitary fibrous tumour of the pleura due to tumour seeding following ultrasound-guided transthoracic biopsy.The scope of educational resources for radiologists on the internet.Assessment of outcomes with delayed (18)F-FDG PET-CT response assessment in head and neck squamous cell carcinoma.Diagnosis of suspected venous thromboembolic disease in pregnancy.Multiple endocrine neoplasia: spectrum of radiologic appearances and discussion of a multitechnique imaging approach.Understanding the internet, website design and intranet development: a primer for radiologists.Pearls and pitfalls of radionuclide imaging of the lymphatic system. Part 1: sentinel node lymphoscintigraphy in malignant melanoma.Radiology education: a glimpse into the future.Genitourinary and breast radiology.Perfusion scintigraphy: diagnostic utility in pregnant women with suspected pulmonary embolic disease.Detection of an occult thymoma on 99Tcm-Tetrofosmin myocardial scintigraphy.Clinical utility of hybrid SPECT-CT in endocrine neoplasia.Clinical impact of (18)F-FDG PET-CT in recurrent stage III/IV melanoma: a tertiary centre Specialist Skin Cancer Multidisciplinary Team (SSMDT) experience.Clinical impact of FDG PET-CT on management decisions for patients with primary biliary tumours.Established, emerging and future roles of PET/CT in the management of colorectal cancer.Preparing for consultant interviews in clinical radiology.Multimodality imaging in hyperparathyroidism.Efficacy of qualitative response assessment interpretation criteria at 18F-FDG PET-CT for predicting outcome in locally advanced cervical carcinoma treated with chemoradiotherapy.FDG PET/CT in oncology: "raising the bar".Tc99m-hepatobiliary iminodiacetic acid (HIDA) scintigraphy in clinical practice.Contemporary nuclear medicine imaging of neuroendocrine tumours.Less commonly used and emerging clinical applications of SPECT-CT in benign and malignant disease.Functional imaging for radiation treatment planning, response assessment, and adaptive therapy in head and neck cancer.FDG PET/CT in infection and inflammation--current and emerging clinical applications.Functional Imaging Biomarkers: Potential to Guide an Individualised Approach to Radiotherapy.PET-CT in the UK: current status and future directions.Radiotherapy response evaluation using FDG PET-CT-established and emerging applications.Clinical impact and diagnostic accuracy of 2-[18F]-fluoro-2-deoxy-d-glucose positron-emission tomography/computed tomography (PET/CT) brain imaging in patients with cognitive impairment: a tertiary centre experience in the UK.Risk of malignancy in pulmonary nodules: A validation study of four prediction models.The Impact of (18)F-FDG PET CT Prior to Chemoradiotherapy for Stage III/IV Head and Neck Squamous Cell Carcinoma.Respiratory-gated (4D) contrast-enhanced FDG PET-CT for radiotherapy planning of lower oesophageal carcinoma: feasibility and impact on planning target volume.Atypical Presentation of Riedel's Thyroiditis: Multifocal Nodular Fibrosis and Resolution with Levothyroxine.
P50
Q24669883-D2C621DA-16C2-48A5-BEFF-BBC6912F799CQ28294052-19CF2942-42FA-481F-9DDA-48C3AFF6418CQ30412504-3E0D1C8E-53FC-40BD-9368-1B4E1BDC46F1Q33812162-0C68E624-95D3-430D-B3F0-BA0B0AE0A8A8Q34617818-356DF6D5-0E10-4BF9-9686-36BCDAA7B33FQ35219168-BEBCB79A-89C2-4419-87C9-3A520FB29356Q35548460-80E5F2A8-7B22-42B7-88BD-8437DD1C7770Q35830998-015B19D3-41DD-4356-8226-2D3486C87BABQ36005224-88C3C470-13E3-4991-8E5B-56D25BE5A51BQ36105909-9EB16DB8-546B-4F86-ABA5-40BC2FC6CCC6Q36295724-4A425F6E-073C-4BD1-A267-572BC84D3576Q36343020-72C0E029-A6E1-42FE-B6C3-C63804B6AC8BQ36426445-7481F0B8-F95D-48F1-B34F-B41739654F98Q36470365-8A908DD0-1E87-4B4B-82FF-1E90EE3DD7ACQ36489809-ADD11533-DCE2-46BD-9B39-6F858E124E9AQ36537348-BDAA73C5-E07C-4E9E-8023-0B59EBC35B80Q36537352-77CF42E8-7029-4DBC-86FE-E58EE64AC5AEQ36753416-E739EE33-57FD-4F90-A1D0-4EEABEFD3425Q36841258-878AF489-12CE-4767-B1EC-4BBE5CA60E22Q37089534-2C27D466-AFB5-405B-BE5F-D868D7386546Q37192805-14D2111B-66B5-4B2E-A369-D72BD3DFEF60Q37192828-8F2DEA6F-8264-44D5-B67C-53D52C36C29DQ37382723-719291D7-9F00-4110-9195-ED3E30381831Q37434792-FEDA2DB8-4E3B-4487-850A-871421E2F263Q37628325-F9565F8D-ABF9-4BB0-835D-2AC8F79222C8Q37662679-1F9989EC-6A93-40EB-8848-294638A67A21Q37764491-E8871A1F-493B-48B3-8D93-DF9ABD8C3E5DQ37921400-29106881-B200-4AE5-B9B3-8C0AE54847CAQ38013360-3ACFF368-AAD0-4428-A96D-3707266AD7D0Q38022423-82078E1B-0013-49DA-B847-351BAF4E19D7Q38162269-64B16E00-D61E-45B4-9184-705FDC2E09F2Q38445244-3D21ECB9-1569-461A-8F73-7D6FADC70CA2Q38541639-D8D53024-D542-4436-A5C6-13645BE5E55BQ38798179-A85E3B0A-B7AC-4F8A-B351-A806A9462963Q39051286-BEF6C66B-73A9-4321-B645-9B05EFB9AAC6Q39380907-BE174C88-F233-4B78-9355-4CB42D022FBEQ41086632-7FE6A7F5-8649-478D-8635-0C58FD803A29Q41938522-FBA07B95-D972-4B3E-8A58-4AF9D6B3494CQ42117858-B9E8C497-9C31-4190-8B94-1324CDF1AD8CQ42155201-B29A0A2D-88D6-4A44-9E76-F2B9BE0EF268
P50
description
Panaliti
@jv
Peneliti
@id
Wetenschopper
@nds
araştırmacı
@tr
badacz
@pl
badatel
@cs
cercetător
@ro
chercheur
@fr
ciencisto
@io
forskar
@nn
name
Andrew F Scarsbrook
@af
Andrew F Scarsbrook
@an
Andrew F Scarsbrook
@ast
Andrew F Scarsbrook
@ay
Andrew F Scarsbrook
@az
Andrew F Scarsbrook
@br
Andrew F Scarsbrook
@ca
Andrew F Scarsbrook
@ce
Andrew F Scarsbrook
@ceb
Andrew F Scarsbrook
@co
type
label
Andrew F Scarsbrook
@af
Andrew F Scarsbrook
@an
Andrew F Scarsbrook
@ast
Andrew F Scarsbrook
@ay
Andrew F Scarsbrook
@az
Andrew F Scarsbrook
@br
Andrew F Scarsbrook
@ca
Andrew F Scarsbrook
@ce
Andrew F Scarsbrook
@ceb
Andrew F Scarsbrook
@co
altLabel
Andrew Scarsbrook
@en
Andy Scarsbrook
@af
Andy Scarsbrook
@an
Andy Scarsbrook
@ast
Andy Scarsbrook
@ay
Andy Scarsbrook
@az
Andy Scarsbrook
@br
Andy Scarsbrook
@ca
Andy Scarsbrook
@ce
Andy Scarsbrook
@ceb
prefLabel
Andrew F Scarsbrook
@af
Andrew F Scarsbrook
@an
Andrew F Scarsbrook
@ast
Andrew F Scarsbrook
@ay
Andrew F Scarsbrook
@az
Andrew F Scarsbrook
@br
Andrew F Scarsbrook
@ca
Andrew F Scarsbrook
@ce
Andrew F Scarsbrook
@ceb
Andrew F Scarsbrook
@co
P106
P1153
8613885700
P1960
VxzIT5IAAAAJ
P2038
Andrew_Scarsbrook
P21
P31
P496
0000-0002-4243-032X
P6634
andy-scarsbrook-11221225